H.C. Wainwright Downgrades Aviragen Therapeutics (AVIR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ladenburg Thalmann Downgrades Aviragen (AVIR) to Neutral
February 14, 2017 8:30 AM ESTLadenburg Thalmann downgraded Aviragen (NASDAQ: AVIR) from Buy to Neutral.
For an analyst ratings summary and ratings history on Aviragen click here. For more ratings news on Aviragen click here.
Shares of Aviragen closed at $1.08 yesterday.
... MoreAviragen Therapeutics' (AVIR) Phase 2b SPIRITUS Trial of Vapendavir Fails
February 13, 2017 4:02 PM ESTAviragen Therapeutics (NASDAQ: AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.
We are disappointed that the... More
